Summary:
Tolerx, a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T cell activity. The company’s pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKline.
Investors 1
| Date | Name | Website |
| - | Rho Ventur... | rhoventure... |
Mentions in press and media 3
| Date | Title | Description | Category | Author | Source |
| 07.10.2011 | Report: To... | Share Share on Facebook Share ... | - | Luke Timme... | xconomy.co... |
| 24.10.2007 | Life scien... | Featured companies: Angstrom M... | - | - | venturebea... |
| 28.09.2007 | Can ToleRx... | Share Share on Facebook Share ... | - | David Stip... | xconomy.co... |